Yunnan Baiyao: Western stencil national brand

"Salvage Grass" is an "Internet violence" incident?

Yunnan Baiyao official website posted on April 17th the source of "WeChat" the "conspiracy - why the national brand for a hundred years was black? "Article, the article will be "toxic" formula incidents attributed to "news hype", directed at behind-the-scenes interest groups.

The previous week, Yunnan Baiyao official website also hanged on April 11th from the Dagong Network's “crazy suppression of Yunnanbaiyao, who is benefiting? "article. The tones and conclusions of the above two articles are strikingly similar. The latter article points to the competitors.

On April 4th, Yunnan Baiyao released a related announcement on the revision of the drug instruction manual, officially announced that its formula contained components of Caudex, and emphasized the safety of its drugs again. The foregoing article believes that Yunnan Baiyao was forced to publish its drug ingredients that belong to the “national secret formula” under the oppression of “cyber violence”.

Wang Hai, who once filed a lawsuit against Yunnan Baiyao, believes that if Yunnan Baiyao believes that there is a plot, it can be investigated carefully to see who is operating or operating it. It is not a matter of simple suspicion. This is to shift the public’s attention. . "Now that many companies begin to shift their topics once problems arise, it is a common practice to transfer contradictions to competitors."

On April 17th and 18th, he called the Yunnan Baiyao Dongwei secretary's telephone number several times to ask him to respond to the "conspiracy theory," but his phone has been in a state of no answer.

"conspiracy"

The article points behind the “pushing hands” of Yunnan Baiyao’s “functionality gate”, “secret gate”, “Caowumen” and other events to “Western powers” ​​with competitive relations, including P&G, Colgate, and Unilever.

Yunnan Baiyao posted on April 17th: "Intrigue - Why is a hundred-year national brand black? The author of the article is unknown. This article tells the story of the “Wan Ying Bao Bao Dan” and the wonder of Yunnan Baiyao’s high growth after market listing in 1993 and the market value of over 40 billion yuan. "Sinister intentions" interest groups and "unscrupulous media people."

This article links a series of events related to the “speculation” of Yunnan Baiyao to the timing of the “people with ulterior motives” and the interest groups of Yunnan Baiyao’s “fat” to use the time to suppress Yunnan Baiyao and suppress its stock price. Together, they came to the conclusion that Yunnan Baiyao was "blackened."

Coincidentally, Yunnan Baiyao also transmitted another site on its official website on April 11th. "Articles. In this article, the “power promoters” of Yunnan Baiyao’s “door of efficacy”, “secret gate”, and “Caowumen” have been heated in recent years to point to “Western powers” ​​with competitive relations, including P&G, Colgate, and Unilever. .

Interestingly, the tone of the above two sentences is very similar to the conclusion, which is the symbolic signal that Yunnan Baiyao began to use the new media platform to defend against attacks after encountering a series of “toxic” recipes.

In fact, in 2003 and 2009 before the Hong Kong Department of Health announced the “toxic” formula of Yunnan Baiyao on February 5, 2013, Yunnan Baiyao’s “poison” problem has caused disputes because of the death caused by poisoning and the occurrence of toxic adverse reactions.

The outsiders thus strongly questioned Yunnan Baiyao's practice of using the “state secret formula” as a shield to ignore the public’s right to know.

In an interview with the media, Yunnan Baiyao Group Deputy Minister of Commerce and the Ministry of Party and Community Affairs stated that the rapid development of Yunnan Baiyao has defeated many competitors, and some people have repeatedly prosecuted Yunnan Baiyao for publicly-requested drug ingredients on the basis of the public’s right to know. It's competitors who do it."

The "conspiracy theory" put forward another important basis is that Yunnan Baiyao obtained an explosive growth after listing in 1993, and many of its products have brought greater impact on competitors. It is said that by 2013, the 20th anniversary of the listing of Yunnan Baiyao. Compared with the beginning of the listing, its operating income increased by 270 times, net profit increased by 150 times, and total assets increased by 72 times. In 2013, only toothpaste was awarded 2.5 billion yuan, an increase of nearly 20%, accounting for 15.82% of the total revenue. "It shows the vigorous vitality of traditional Chinese medicine in modern society."

The "conspiracy theory" said that in the past decade or so, Yunnan Baiyao began to compete more and more directly with western multinational corporations through its "big health" strategy. Yunnan Baiyao was therefore “black”, and the “Caowu Event” was followed by “cooking”.

question

The publication of some toxic formulas does not lead to leakage of secret formulas. The fundamental way to solve the intellectual property rights of national grade drugs is to apply for international patents, instead of ignoring consumers.

Under pressure from society and public opinion, Yunnan Baiyao, which has been plagued by “toxic” formulas in recent years, issued an announcement on April 4 to revise its drug product specification, and once again emphasized the safety of its products.

The aforementioned "conspiracy theory" author believes that Yunnan Baiyao was forced to publish "national secret formulas" under the oppression of "cyber violence." However, an unavoidable problem is that Yunnan Baiyao's pharmaceutical formula does contain “Caowu” ingredients, which have previously been concealed as a “state secret formula”.

According to Pharmacopoeia data, Aconitum is very spicy, bitter and toxic. Its main ingredient, Aconitum alkaloids, can cause symptoms such as paralysis of the lips and extremities, nausea, vomiting, and weakness in limbs. Severe cases can also cause life-threatening conditions.

According to a notice issued by the Hong Kong Department of Health on February 5, 2013, “A follow-up investigation was conducted after receiving relevant information”. The Hong Kong Government Laboratory found that samples of proprietary Chinese medicine contained unlabeled aconitine alkaloids. According to the product registration data and the literature on traditional Chinese medicines, the components of the proprietary Chinese medicines should not contain the aconitum alkaloids that have been tested. Therefore, this order is recycled.

According to media reports, in 2003, a patient in Guangzhou died of poisoning due to overdose of Yunnanbaiyao, and Zhao Yin, who filed a lawsuit against Yunnanbaiyao in 2009, filed a lawsuit only after taking his own Yunnan Baiyao poisoning and consulting a large amount of Pharmacopoeia data.

Zhao Yin believes that the Yunnan Baiyao Manual has warning flaws. The warnings for toxicity and adverse reactions are not strictly disclosed. As a listed company, Yunnan Baiyao should be responsible to consumers.

Nowadays, in the face of the crisis, the “conspiracy theory” thrown by Yunnan Baiyao has also been questioned by professional counterfeiters. Wang Hai, a professional swindler who had filed a lawsuit against Yunnan Baiyao, believes that if Yunnan Baiyao believes that there is a conspiracy, it may be through careful investigation to see who is operating or operating it, rather than simply doubting it. This is to divert the public's attention.

Wang Hai said that now that many companies begin to shift their topics once they have problems, it is a common practice to transfer contradictions to their competitors. “Yunnan Baiyao did not correct its mistakes after they had a problem, and instead of apologizing, it thrown out a 'conspiracy theory'. meaningless".

In fact, even if many consumers questioned Yunnan Baiyao’s use of the “state secret formula” as a shield and refused to publicly formulate ingredients and ignore consumer’s right to know and health, in February 2013, the Hong Kong Department of Health released its “ Prior to the toxic formula, Yunnan Baiyao did not promptly label the toxic components of the drug.

Some experts also have different opinions on Yunnan Baiyao's refusal to announce drug formulations before April 4.

Sun Xiaobo, deputy director of the Institute of Medicinal Plants of the Chinese Academy of Medical Sciences, believes that “publishing some toxic formulas will not lead to disclosure of secret formulas. The fundamental way to solve the intellectual property rights of national pharmaceuticals is to apply for international patents, rather than ignoring consumers. ”

Reflection

For Yunnan Baiyao Company, it is necessary to reflect on whether to deal with the problem of late-stage market competition, whether it is done well after the use of drugs, and whether adverse reactions caused by toxic drugs have attracted sufficient attention.

Du Shilin, an expert in law at the Humanities and Social Sciences College of Southern Medical University, believes that the Yunnan Baiyao incident involves many legal issues, the most important of which is the conflict between the protection of intellectual property rights of Chinese medicine and the protection of consumers’ right to information.

In fact, even after the publication of an announcement to amend the specifications of the drug on April 4, Yunnan Baiyao simply marked a simple description of the “Caowu composition” component. Consumers’ right to information is still not fully reflected. It is difficult to eliminate the public’s suspicions of “toxic” drugs.

However, in response to widespread public concern about the part of the White Drugs product that was banned by the Hong Kong Department of Health in February 2013, Yunnan Baiyao announced that after the company cooperated with the Department of Health of Hong Kong to supplement and improve the relevant product registration procedures, the Hong Kong Department of Health had agreed to resume the shelves and Since November 2013, it has resumed normal sales in Hong Kong.

According to the data, Yunnan Baiyao achieved revenue of 15.8 billion yuan in 2013, an increase of 16%, and a net profit of 2.32 billion yuan, an increase of 47%. However, in 2013, Yunnan Baiyao suffered heavy losses in its overseas businesses such as Hong Kong and Macao, and its overseas business division saw a drop in operating income. 14%.

Yin Pinyao, general manager of Yunnan Baiyao Group, acknowledged that the decline in revenue growth in the overseas markets was mainly due to the “aconitine incident” in Hong Kong. Hong Kong was a major overseas market for Baiyao, which affected the company’s product sales.

According to reports, the next step in Yunnan Baiyao will vigorously promote Yang Yuanqing laundry detergent, Qing Yi Tang sanitary napkins and other products, in the fast-dispelling areas, which will obviously cause competitors to strongly rebound.

According to Yunnan Baiyao’s plan, new products such as Yuanyang Shampoo and Qingyitang “Daily” sanitary napkins will be launched in 2014, aiming at high-end markets controlled by foreign capital. It is foreseeable that market participants believe that the “feature door” and “toxic door” incident will repeat itself.

One middle-aged employee of Yunnan Baiyao, who has left, said that the company will face more “people with ulterior motives” in the future. Therefore, they must first “use their minds”. While doing drugs, they must also “catch up with the times” in developing ideas. "Introduction" and "Yunnan Baiyao's use of 'conspiracy theory' may be counterproductive."

Some experts believe that for Yunnan Baiyao Company, it is necessary to reflect on whether it is to deal with the problems of market competition in the later period. Is it a good follow-up work after the drug is used? Does the toxic drug's adverse reactions cause enough attention? . In addition, whether Yunnan Baiyao put aside the “national secret recipe” and made objective and scientific changes to its drug specifications.

"For the relevant departments of the country, it is necessary to strengthen the monitoring of the safety of traditional Chinese medicines, but also to strengthen the supervision of traditional Chinese medicine companies to ensure the safety of consumers or patients, if the relevant laws and regulations lag, it should be revised in time." Du Shilin said.

Undoubtedly, the traditional Chinese medicine industry represented by Yunnan Baiyao faces common problems: Chinese medicine needs to have a precise description of standardization, standardization, and unification.

"It is regrettable that we are too late to promote the development of traditional Chinese medicine in our legal system," said Pan Changxin, associate professor of law at Shandong University, in an interview with the media.